Theravance Biopharma
TBPH
121 hedge funds and large institutions have $600M invested in Theravance Biopharma in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 44 increasing their positions, 38 reducing their positions, and 14 closing their positions.
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
16% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 38
4% more funds holding
Funds holding: 116 → 121 (+5)
2.5% more ownership
Funds ownership: 80.53% → 83.03% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less capital invested
Capital invested by funds: $655M → $600M (-$54.8M)
74% less call options, than puts
Call options by funds: $1.49M | Put options by funds: $5.71M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$27.5M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$7.36M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.35M |
| 4 |
Goldman Sachs
New York
|
+$6.2M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$6.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$26.7M |
| 2 |
Morgan Stanley
New York
|
-$7.93M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$7.25M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$5.53M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.79M |
TBPH Hedge Fund Activity: Q1 2022 in Review
121 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2022, worth a combined $600M — down 8.4% from $655M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new TBPH positions and 14 closed out — a net gain of 5 holders — while 44 added to existing stakes and 38 trimmed.
The largest buyer was Weiss Asset Management, adding an estimated $27.5M. The largest seller was OrbiMed, cutting an estimated $26.7M.
- 121 institutional investors held Theravance Biopharma (TBPH) as of Q1 2022, up from 116 in Q4 2021.
- Funds reported $600M of Theravance Biopharma stock for Q1 2022, down 8.4% quarter-over-quarter.
- 19 funds opened new Theravance Biopharma positions in Q1 2022 and 14 closed out, a net change of +5 holders.
- The largest Theravance Biopharma buyer in Q1 2022 was Weiss Asset Management, an estimated $27.5M added.
- The largest Theravance Biopharma seller in Q1 2022 was OrbiMed, an estimated $26.7M sold.
Based on aggregated 13F filings for Q1 2022.